Purified Interferon As Protection Against Rhinovirus Infection

In a double-blind placebo-controlled study a preparation of human leucocyte interferon purified by affinity chromatography using a monoclonal antibody and applied by repeated nasal sprays reduced the incidence and severity of colds in volunteers challenged with human rhinovirus 9. Although interfero...

Full description

Saved in:
Bibliographic Details
Published inBritish medical journal (Clinical research ed.) Vol. 284; no. 6332; pp. 1822 - 1825
Main Authors Scott, G. M., Phillpotts, R. J., Wallace, J., Secher, D. S., Cantell, K., Tyrrell, D. A. J.
Format Journal Article
LanguageEnglish
Published England British Medical Association 19.06.1982
BMJ Publishing Group LTD
Subjects
Administration, Intranasal
Antibodies
Clinical Research
Clinical Trials as Topic
Common Cold - prevention & control
Dosage
Double-Blind Method
Human experimentation
Humans
Infections
Interferons
Interferons - administration & dosage
Interferons - therapeutic use
Nasal lavage fluid
Nose - microbiology
Placebos
Rhinovirus
Rhinovirus - isolation & purification
Viruses
Volunteerism
Online AccessGet full text

Cover

More Information
Summary:In a double-blind placebo-controlled study a preparation of human leucocyte interferon purified by affinity chromatography using a monoclonal antibody and applied by repeated nasal sprays reduced the incidence and severity of colds in volunteers challenged with human rhinovirus 9. Although interferon itself caused some symptoms, these were minor compared with the clinical colds. Interferon activity was still detectable in nasal washings as long as 26 hours after the last dose in about half the volunteers on active treatment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:0267-0623
DOI:10.1136/bmj.284.6332.1822